The impact of fungal infections reaffirm the value of research into the ways that fungi infect humans, and how these infections can be detected, identified and treated.
A 2018 paper jointly published by three leading infectious disease organizations (APIC, SHEA, and SIDP) stated that infection prevention and control and antibiotic stewardship programs are inextricably linked.
The farthest-along candidates are a viral vector vaccine being tested by the University of Oxford and AstraZeneca, a repurposed vaccine, originally developed in the early 1900s for protection against tuberculosis, and a whole-virus vaccine being tested by the state-owned Chinese company Sinopharm.
Companies and organizations that provide diagnostics serve an important role and must overcome many challenges inherent to developing diagnostic solutions. These areas include research and development, the regulatory environment, production and manufacturing, commercialization, and insurance and reimbursement.